ASS234

multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.

General

Type : Multitarget, Monoamine-oxidase-inhibitor, Alkyl linked bis-ligand, Piperidine, Indole

Chemical_Nomenclature : N-[[5-[3-(1-benzylpiperidin-4-yl)propoxy]-1-methylindol-2-yl]methyl]-N-methylprop-2-yn-1-amine

Canonical SMILES : CN1C2=C(C=C(C=C2)OCCCC3CCN(CC3)CC4=CC=CC=C4)C=C1CN(C)CC#C

InChI : InChI=1S\/C29H37N3O\/c1-4-16-30(2)23-27-20-26-21-28(12-13-29(26)31(27)3)33-19-8-11-24-14-17-32(18-15-24)22-25-9-6-5-7-10-25\/h1,5-7,9-10,12-13,20-21,24H,8,11,14-19,22-23H2,2-3H3

InChIKey : ADCBAOTWERXLAP-UHFFFAOYSA-N

Other name(s) : CHEMBL1929421  ||  D0C1LI  ||  GTPL7369  ||  SCHEMBL6847307  ||  ASS-234


MW : 443.63

Formula : C29H37N3O

CAS_number :

PubChem : 53378764

UniChem : ADCBAOTWERXLAP-UHFFFAOYSA-N

Target

Families : ASS234 ligand of proteins in family
ACHE

References (11)

Title : Highlights of ASS234: a novel and promising therapeutic agent for Alzheimer's disease therapy - Romero_2020_Neural.Regen.Res_15_30
Author(s) : Romero A , Marco-Contelles J , Ramos E
Ref : Neural Regen Res , 15 :30 , 2020
Abstract :
PubMedSearch : Romero_2020_Neural.Regen.Res_15_30
PubMedID: 31535639

Title : Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3 R Antagonism for Neurodegenerative Diseases - Bautista-Aguilera_2017_Angew.Chem.Int.Ed.Engl_56_12765
Author(s) : Bautista-Aguilera OM , Hagenow S , Palomino-Antolin A , Farre-Alins V , Ismaili L , Joffrin PL , Jimeno ML , Soukup O , Janockova J , Kalinowsky L , Proschak E , Iriepa I , Moraleda I , Schwed JS , Romero Martinez A , Lopez-Munoz F , Chioua M , Egea J , Ramsay RR , Marco-Contelles J , Stark H
Ref : Angew Chem Int Ed Engl , 56 :12765 , 2017
Abstract :
PubMedSearch : Bautista-Aguilera_2017_Angew.Chem.Int.Ed.Engl_56_12765
PubMedID: 28861918

Title : The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease - Serrano_2017_J.Psychiatry.Neurosci_42_59
Author(s) : Serrano MP , Herrero-Labrador R , Futch HS , Serrano J , Romero A , Fernandez AP , Samadi A , Unzeta M , Marco-Contelles J , Martinez-Murillo R
Ref : J Psychiatry Neurosci , 42 :59 , 2017
Abstract :
PubMedSearch : Serrano_2017_J.Psychiatry.Neurosci_42_59
PubMedID: 27636528

Title : In-vitro and in-vivo evaluation of the modulatory effects of the multitarget compound ASS234 on the monoaminergic system - Esteban_2017_J.Pharm.Pharmacol_69_314
Author(s) : Esteban G , Van Schoors J , Sun P , Van Eeckhaut A , Marco-Contelles J , Smolders I , Unzeta M
Ref : J Pharm Pharmacol , 69 :314 , 2017
Abstract :
PubMedSearch : Esteban_2017_J.Pharm.Pharmacol_69_314
PubMedID: 28134992

Title : ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy - Marco-Contelles_2016_Front.Neurosci_10_294
Author(s) : Marco-Contelles J , Unzeta M , Bolea I , Esteban G , Ramsay RR , Romero A , Martinez-Murillo R , Carreiras MC , Ismaili L
Ref : Front Neurosci , 10 :294 , 2016
Abstract :
PubMedSearch : Marco-Contelles_2016_Front.Neurosci_10_294
PubMedID: 27445665

Title : Upregulation of Antioxidant Enzymes by ASS234, a Multitarget Directed Propargylamine for Alzheimer's Disease Therapy -
Author(s) : Ramos E , Romero A , Marco-Contelles J , Del Pino J
Ref : CNS Neurosci Ther , 22 :799 , 2016
PubMedID: 27380946

Title : Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease - Esteban_2014_Biochim.Biophys.Acta_1844_1104
Author(s) : Esteban G , Allan J , Samadi A , Mattevi A , Unzeta M , Marco-Contelles J , Binda C , Ramsay RR
Ref : Biochimica & Biophysica Acta , 1844 :1104 , 2014
Abstract :
PubMedSearch : Esteban_2014_Biochim.Biophys.Acta_1844_1104
PubMedID: 24642166

Title : Wnt signaling pathway, a potential target for Alzheimer's disease treatment, is activated by a novel multitarget compound ASS234 -
Author(s) : Del Pino J , Ramos E , Aguilera OM , Marco-Contelles J , Romero A
Ref : CNS Neurosci Ther , 20 :568 , 2014
PubMedID: 24712554

Title : Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia - Stasiak_2014_Curr.Pharm.Des_20_161
Author(s) : Stasiak A , Mussur M , Unzeta M , Samadi A , Marco-Contelles JL , Fogel WA , Marco-Contelles J
Ref : Curr Pharm Des , 20 :161 , 2014
Abstract :
PubMedSearch : Stasiak_2014_Curr.Pharm.Des_20_161
PubMedID: 23701539

Title : Multipotent, permeable drug ASS234 inhibits Abeta aggregation, possesses antioxidant properties and protects from Abeta-induced apoptosis in vitro - Bolea_2013_Curr.Alzheimer.Res_10_797
Author(s) : Bolea I , Gella A , Monjas L , Perez C , Rodriguez-Franco MI , Marco-Contelles J , Samadi A , Unzeta M
Ref : Curr Alzheimer Res , 10 :797 , 2013
Abstract :
PubMedSearch : Bolea_2013_Curr.Alzheimer.Res_10_797
PubMedID: 23919774

Title : Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase\/monoamine oxidase inhibitors for the treatment of Alzheimer's disease - Bolea_2011_J.Med.Chem_54_8251
Author(s) : Bolea I , Juarez-Jimenez J , de los Rios C , Chioua M , Pouplana R , Luque FJ , Unzeta M , Marco-Contelles J , Samadi A
Ref : Journal of Medicinal Chemistry , 54 :8251 , 2011
Abstract :
PubMedSearch : Bolea_2011_J.Med.Chem_54_8251
PubMedID: 22023459